v3.24.1.u1
Overview and Basis of Presentation (Details) - USD ($)
$ in Millions
12 Months Ended
Mar. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Mar. 31, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Cash, cash equivalents, and marketable securities       $ 714.3
Alnylam Pharmaceuticals, Inc.        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Payments associated with license agreement   $ 17.5    
Potential development milestone payments, maximum   $ 130.0    
2010 Agreement        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Milestone payment for achievement of specified ex-U.S. commercial milestone event $ 25.0      
Discontinued Operations, Disposed of by Sale | Agios Oncology Business        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Cash proceeds 1,800.0      
Contingent milestone payment $ 200.0      
Discontinued Operations, Disposed of by Sale | Agios Oncology Business | TIBSOVO | UNITED STATES        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Contingent royalty payment 5.00%      
Gain on sale of contingent payments     $ 127.9  
Discontinued Operations, Disposed of by Sale | Agios Oncology Business | Vorasidenib | UNITED STATES        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Contingent royalty payment 15.00%